# Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

Study · id `cardio:ct-nct04239950` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04239950](<https://clinicaltrials.gov/study/NCT04239950>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04239950

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 316 participants.

## Technical summary

Registry record NCT04239950. Randomized; quadruple masking; primary purpose treatment. Start 2020-05-09 (actual); primary completion 2023-07-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 316 participants (enrolled count; ClinicalTrials.gov record NCT04239950, source copy `cardio:ctgov-nct04239950-2024-07-15`, retrieved 2026-10-31)
- Started: 2020-05-09 (actual) (ClinicalTrials.gov record NCT04239950, source copy `cardio:ctgov-nct04239950-2024-07-15`, retrieved 2026-10-31)
- Primary completion: 2023-07-20 (actual) (ClinicalTrials.gov record NCT04239950, source copy `cardio:ctgov-nct04239950-2024-07-15`, retrieved 2026-10-31)
- Completion: 2023-07-20 (actual) (ClinicalTrials.gov record NCT04239950, source copy `cardio:ctgov-nct04239950-2024-07-15`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04239950, source copy `cardio:ctgov-nct04239950-2024-07-15`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04239950-2024-07-15`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia
- Condition: Hypertriglyceridemia
- Intervention (Drug): Placebo
- Intervention (Drug): Ethyl Icosapentate
- Lead sponsor: Mochida Pharmaceutical Company, Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Mochida Pharmaceutical Company, Ltd. (`cardio:org-mochida-pharmaceutical-company-ltd`)
- Registry lists this organization as a collaborator: Marubeni Pharmaceuticals (Suzhou) Co., Ltd. (`cardio:org-marubeni-pharmaceuticals-suzhou-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of highly purified ethyl icosapentate soft capsules (MND-21) for the treatment of severe hypertriglyceridemia: A 12-week, multi-center, placebo-controlled, randomized, double-blind, phase III clinical trial in China (`cardio:pubmed-41500861`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 50030282e3e60ad4c994f5a8721026c2e50a275263f7657081c25d681b9638fc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
